[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557224":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":10,"locations":24,"responsibleParty":38,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":10,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":10,"overallStatus":57,"whyStopped":10,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Far Eastern Memorial Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"intravenous chemotherapy",null,"triweekly chemotherapy with carboplatin AUC=5\\~6 + liposomal-doxorubicin 30\\~40mg\u002Fm2 or paclitaxel 175mg\u002Fm2 0r docetaxel 60\\~75mg\u002Fm2",[13],"Drug: Chemotherapy",{"label":15,"type":10,"description":16,"interventionNames":17},"intraperitoneal chemotherapy","Day 1 IV Paclitaxel 135 mg\u002Fm2 + IP Cisplatin 75-100 mg\u002Fm2 or IP carboplatin (AUC = 6) Day 8 IP Paclitaxel 60 mg\u002Fm2 Every 21 days \\* 6 cycles\n\nOR\n\nDay 1 IP Carboplatin AUC=5 or IP Cisplatin 50-75mg\u002Fm2 Day 2 IV Liposomal doxorubicin 15 mg\u002Fm2 + IP Liposomal doxorubicin 15 mg\u002Fm2 Every 28 days \\* 6 cycles",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DRUG","Chemotherapy","Intravenous chemotherapy versus intraperitoneal chemotherapy in recurrent ovarian cancer",[15,9],[25],{"facility":26,"status":10,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":10},"Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital","Banqiao District","New Taipei","22050","Taiwan","TW",{"type":33,"coordinates":34},"Point",[35,36],121.46719,25.01427,{"lat":36,"lon":35},{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Sheng-Mou Hsiao","Professor","100557224","intraperitoneal-chemotherapy-in-recurrent-ovarian-cancer-100557224",false,"NCT06535334","Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer","Intravenous Chemotherapy Versus Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer","Inclusion Criteria:\n\n* women who had recurrent ovarian cancer and was treated with either intravenous or intraperitoneal platinum based chemotherapy\n\nExclusion Criteria:\n\n* women who did not complete the designated treatment course (exception to those who had to quit due to progressive disease or death of any cause)","FEMALE","20 Years",{"count":52,"type":53},80,"ESTIMATED","OBSERVATIONAL","This study aims to compare intravenous chemotherapy versus intraperitoneal chemotherapy in patients with recurrent ovarian cancer.",[47],"NOT_YET_RECRUITING","2024-07-31",{"date":60,"type":61},"2024-08-02","ACTUAL",{"date":63,"type":53},"2024-08-15",{"date":65,"type":53},"2026-05",{"name":5,"class":6},1]